In 1977, the US Food and Drug Administration (FDA) made a significant decision to ban women of childbearing age from participating in early drug trials. This ban was a direct response to the tragic consequences of drugs like thalidomide, which had been linked to severe birth defects. Even after the ban was lifted for non-pregnant women in 1993, women and female animals continued to be excluded from research studies. Their fluctuating hormone levels were often viewed as complicating factors that could skew the results of the research. As a result, female data was frequently extrapolated from studies conducted on male subjects.
The exclusion of women from medical research has had far-reaching implications. It has distorted our understanding of various health conditions and diseases, leaving us with incomplete and sometimes inaccurate information, particularly in areas that predominantly affect women. One striking example of this disparity occurred in 2013 when the FDA revised the recommended dosage of the sleep aid zolpidem for women, as they were found to experience more daytime drowsiness than men, leading to an increased risk of driving accidents.
Thankfully, there has been progress in recent years as researchers increasingly recognize the importance of considering sex as a biological variable in their studies. This shift in perspective has led to important discoveries, such as the fact that women are twice as likely as men to be diagnosed with depression and that they develop cardiovascular disease at lower levels of blood pressure.
However, there is still much work to be done to address the gender gap in medical research. While many funding agencies now require studies to include both sexes, conditions that predominantly affect women, such as migraine, endometriosis, and premenstrual dysphoric disorder (PMDD), continue to receive disproportionately less funding relative to their impact on the population. The complexity of researching hormonal influences should not be a deterrent but rather a reason to invest more resources into understanding these conditions.
If these conditions primarily affected men, it is likely that there would be more available treatments and research dedicated to finding solutions. The experiences of individuals living with PMDD serve as a poignant reminder of the consequences of gender inequality in medical research and healthcare.
As we strive for greater gender equity in medical research, it is essential to address the existing disparities and allocate resources accordingly to ensure that all individuals receive the care and attention they deserve.
